Australia is eagerly awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://giant-bicycle-road-bike834312.starsblogger.com/313455/this-new-drug-retatrutide-australia-a-new-solution-for-obesity-treatment